Are you addressing known drivers of disease progression in advanced HR+, HER2-negative breast cancer?

The ER pathway in advanced HR+ breast cancer

The ER pathway is a key driver of tumor cell growth and proliferation in HR+, HER2-negative breast cancer.1-3

Endocrine therapy is the recommended initial treatment for advanced HR+, HER2-negative breast cancer.4

Patients may progress faster than you think

In the BOLERO-2 trial, following progression on an NSAI,

50%

of patients in the endocrine monotherapy arm were estimated to have progressed at 3.2 months.5

Activation of additional pathways may drive advanced HR+, HER2-negative breast cancer progression1,2

Up to 70% of breast cancer cases have mutations in the mTOR pathway9
Alternate pathways in  advanced HR+ breast cancer progression

In advanced HR+, HER2-negative breast cancer, targeting only the ER pathway may not be enough.1,2

Dual inhibition of the ER and mTOR pathways is a rational treatment approach to addressing disease progression in this setting1,2

Abbreviations: BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; mTOR, mammalian target of rapamycin; NSAI, nonsteroidal aromatase inhibitor; PFS, progression-free survival.